2,3-Diphenylpropylamine

Last updated
2,3-Diphenylpropylamine
2,3-diphenylpropylamine.svg
Names
Preferred IUPAC name
2,3-Diphenylpropan-1-amine
Identifiers
3D model (JSmol)
ChemSpider
ECHA InfoCard 100.024.099 OOjs UI icon edit-ltr-progressive.svg
PubChem CID
UNII
  • InChI=1S/C15H17N/c16-12-15(14-9-5-2-6-10-14)11-13-7-3-1-4-8-13/h1-10,15H,11-12,16H2 Yes check.svgY
    Key: RHRYWWVGUVEZRJ-UHFFFAOYSA-N Yes check.svgY
  • C1=CC=C(C=C1)CC(CN)C2=CC=CC=C2
Properties
C15H17N
Molar mass 211.308 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
X mark.svgN  verify  (what is  Yes check.svgYX mark.svgN ?)
Infobox references

2,3-Diphenylpropylamine is a form of diphenylpropylamine.


Related Research Articles

Levomoramide

Levomoramide is the inactive isomer of the opioid analgesic dextromoramide, invented by the chemist Paul Janssen in 1956. Unlike dextromoramide, which is a potent analgesic with high abuse potential, levomoramide is virtually without activity.

Trimethyldiphenylpropylamine

Trimethyldiphenylpropylamine (N,N,1-Trimethyl-3,3-diphenylpropylamine) is a drug used for functional gastrointestinal disorders. Its tradename is Recipavrin.

The molecular formula C18H23N (molar mass: 253.382 g/mol) may refer to:

Diphenylpropylamine is a propylamine derivative and may refer to:

3,3-Diphenylpropylamine Chemical compound

3,3-Diphenylpropylamine is a form of diphenylpropylamine.

The molecular formula C15H17N (molar mass: 211.30 g/mol, exact mass: 211.1361 u) may refer to:

Selective serotonin reuptake inhibitors, or serotonin-specific re-uptake inhibitor (SSRIs), are a class of chemical compounds that have contributed to the major advances as antidepressants where they have revolutionised the treatment of depression and other psychiatric disorders. The SSRIs are therapeutically useful in the treatment of panic disorder (PD), posttraumatic stress disorder (PTSD), social anxiety disorder, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder (PMDD) and anorexia. There is also clinical evidence of SSRIs efficiency in the treatment of the negative symptoms of schizophrenia and their ability to prevent cardiovascular diseases.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.